Abstract
Imipenem (MK-0787), a new carbapenem antibiotic, combined with cilastatin sodium (MK-0791), was studied clinically and microbiologically. The following results were obtained:
1. Concentrations of MK-0787 in the plasma and internal genital tissues were measured at 1 hour after an intravenous drip infusion of MK-0787/MK-0791 (500mg/500mg) for 30 minutes.
Mean plasma levels higher than 11.8μg/ml and mean tissue levels higher than 2.3 μg/g were observed.
When its MIC values are considered, MK-0787/MK-0791 appeared to be bactericidal against many Grampositive and Gram-negative bacteria except some Pseudomosas sp. and Enterococcus faecium.
2. Clinical effects of the therapy with MK-0787/MK-0791 (500mg/500mg) using a drip infusion twice daily were evaluated in 3 patients with pyometra and 3 patients with BARTHOLIN'S gland abscess. Clinical responses were good in 5 of the 6 patients.
One patient with pyometra due to E. coli didn't respond to the therapy. No side effects or abnormal laboratory findings due to the drug were noted.
